

Insulin delivery using pen devices

Simple-to-use tools may help young and old alike

Nancy J. V. Bohannon, MD

Preview: Clinical trials have convincingly demonstrated that improved glycemic control significantly reduces the risk of diabetes-related complications. However, tight control is not always easy for patients to achieve. To help overcome some of the problems linked with tight control, insulin pen devices have been developed to offer easier, safer, more accurate, and more discreet insulin injection. In this article, Dr Bohannon provides information about these insulin pens and discusses which patients are most likely to benefit.

Bohannon NJV. Insulin delivery using pen devices: simple-to-use tools may help young and old alike. Postgrad Med 1999;106(5):57-68

With the rapid pace of modern life, the time required to optimally manage diabetes may be hard to find. New insulin and insulin delivery systems can make this easier while offering additional benefits of lifestyle flexibility and improved glycemic control. Insulin analogues, such as insulin lispro (Humalog), also improve convenience by their rapid action; this allows insulin injection immediately before meals, rather than the 30- to 60-minute interval needed for the best postprandial glucose control with regular insulin.

Insulin pens are another innovation designed to provide the patient with an easy-to-use, convenient, and accurate method of insulin delivery. The goal is to improve glycemic control by making it less difficult to follow the current recommendations for intensive insulin regimens.

Two types of insulin pens are available today: prefilled and reusable. Prefilled pens are simply discarded when the insulin cartridge is spent, whereas reusable pens contain a replaceable insulin cartridge that is loaded into and removed from the pen by the patient. Most pens function on simple mechanical principles and are durable. The technique for insulin delivery is similar for both prefilled and reusable pens.

Technical advances

Medical therapy for diabetes mellitus has changed dramatically since Banting and Best discovered insulin in 1921. Not only have therapies for diabetes advanced significantly, but the technology for the delivery of insulin has also changed. Nonetheless, syringes were the sole method of insulin delivery for decades. The original glass syringes and their large, reusable needles had to be boiled for sterilization. The needles were sharpened with a pumice stone for reuse. Syringes continue to play a prominent role in patient care today, but they are now disposable plastic devices that deliver as little as 0.5-unit dosing increments through 30-gauge, short, attached needles.

Although advancements in technology have provided various sizes of syringes and needle systems, the traditional insulin injection process remains time-consuming, cumbersome, inconvenient, and somewhat painful. Furthermore, insulin dosing via syringe is associated with a high risk of dosage errors; as many as 80% of patients carry out some aspect of insulin administration via syringe incorrectly (1). Now, to allow more flexibility and convenience, patients are seeking options other than the traditional vial-and-syringe delivery method. Insulin pens meet this need and also address issues of patient and environmental safety, social concerns, and more accurate dosage control (table 1).

Table 1. Advantages of insulin pen devices over conventional insulin syringes

More convenient insulin delivery
More accurate dosing
Less pain because smaller-gauge needles are used
Better quality of life
Easier compliance with insulin regimen
Simpler for specific populations to use (eg, older adults, children and adolescents, pregnant women)
Improved social acceptability, especially at school
More flexibility because of disposable or reusable options

Insulin pen devices are unique in that they combine the insulin container and the syringe in a single unit. Their compact size allows discreet insulin administration but still provides extremely accurate insulin delivery. Advances in the technology of needle manufacturing continue to make needles more comfortable to use (2). With all these refinements combined, insulin pens improve the likelihood that patients will adhere more closely to recommended insulin dosing schedules.

Pen types and styles

Insulin pens have become extremely popular throughout the world; in some countries, 70% to 90% of all insulin is delivered by pen (3). However, in the United States only about 2% of insulin is injected via pen. This is probably because of difficulties with reimbursement from insurance companies or a lack of knowledge on the part of patients and physicians about pen availability. The fact is that insulin pens are available in various types and styles (table 2) and can benefit a large number of patients.

Table 2. Features of commercially available insulin pen devices

	B-D Pen Classic 1.5 mL (Becton Dickinson)	B-D Pen Mini (Becton Dickinson)	Autopen AN 3000, AN 3100 (Owen Mumford)	Humalog, Humulin pens (R, NPH, 70/30) 3.0 mL (Lilly)	NovoPen 1.5 mL (Novo Nordisk)	NovoPen 3.0 mL (Novo Nordisk)	Novolin Prefilled pen (R, NPH, 70/30) 1.5 mL (Novo Nordisk)	Disetronic pen 3.15 mL (Disetronic)
Physical characteristics								
Prefilled	N	N	N	Y	N	N	Y	N
Reusable	Y	Y	Y	N	Y	Y	N	Y
1.5 mL, 150 units	Y	Y	Y	N	Y	N	Y	N
3.0 mL, 300 units	N	N	N	Y	N	Y	N	N
3.15 mL, 315 units	N	N	N	N	N	N	N	Y
Pediatric "POP" pens	Y	Y	N	N	N	N	N	N
Special color graphics	Y	N	N	N	Y	Y	N	N
Viewed size of dose numbers greater than or equal to 0.1 in. (or clip-on magnifier)	N	N	Y	Y	N	N (Y)	N	Y

Table 2. Features of commercially available insulin pen devices

	B-D Pen Classic 1.5 mL (Becton Dickinson)	B-D Pen Mini (Becton Dickinson)	Autopen AN 3000, AN 3100 (Owen Mumford)	Humalog, Humulin pens (R, NPH, 70/30) 3.0 mL (Lilly)	NovoPen 1.5 mL (Novo Nordisk)	NovoPen 3.0 mL (Novo Nordisk)	Novolin Prefilled pen (R, NPH, 70/30) 1.5 mL (Novo Nordisk)	Disetronic pen 3.15 mL (Disetronic)
Dosing features								
Manufacturer's stated dosing increment (units)	1	0.5	3000, 1 3100, 2	1	1	1	2	1
Minimum/maximum dose (units)	1/30	0.5/15	3000, 1/16 3100, 2/32	1/60	1/40	2/70	2/58	1/80
Dark dosing number on light background	Y	Y	N	Y	N	N	Y	Y
Dial and dose using same knob	Y	Y	N	Y	Y	Y	N	Y
Two-way dose dialing	N	N	N	Y	N	N	Y	Y
Audible click when dialing	Y	Y	Y	Y	Y	Y	Y	Y
Audible click when injecting	Y	Y	N	N	Y	Y	N	Y
End of injection stroke indication	Y	Y	N	Y	Y	Y	N	Y
Insufficient remaining dose (predose indication)	N	N	Y	Y	N	N	Y	Y
Indicator returns to zero at dose completion	Y	Y	Y	N	Y	Y	Y	N

N, no; NPH, isophane insulin suspension; R, regular insulin; Y, yes.

Prefilled pens

Prefilled pens contain a built-in, single-use insulin cartridge. Because this device requires no loading by the patient, it is especially convenient and easy to use. These portable, durable, and lightweight delivery systems are particularly helpful for patients who have difficulty handling the cartridges in reusable pens or people with busy schedules who prefer not to have to stop to change cartridges. However, prefilled pens may be slightly more expensive over time, compared with reusable pens. Also, both types of pens are more expensive than vial-and-syringe insulin therapy.

In the United States, the first prefilled pen was the Novolin 70/30, introduced in 1993; the newest prefilled pens are the insulin lispro (Humalog) and human insulin (Humulin) devices manufactured by Eli Lilly & Company. These pens have single-unit dosing increments, audible clicks when dialing the dose, a large magnifying window that shows unit dose, two-way dose setting that allows the user to decrease the dose without taking the pen apart or discharging insulin from the pen, and an end-of-dose click that indicates that the full dose has been delivered.

Reusable pens

With the reusable pen, the patient inserts an insulin cartridge into the pen's delivery chamber. For some patients, this

allows greater flexibility (ie, changing types of insulin without needing to buy another pen if prescription changes), and it may be more economical than using prefilled pens. In addition to being durable and easy to use, the reusable pens are designed for longer duration of use. Disadvantages of the reusable pens are the potential loss of sterility with use (4,5) and the possible damage that may occur to the pen over time.

With individual use of the pen device, the risk of infection is minimized (5). Among the reusable pens currently on the US market are: Autopen AN 3000 and AN 3100 (Owen Mumford, Inc.), B-D Pen Classic and B-D Pen Mini (Becton Dickinson), Novo-Pen 1.5 and NovoPen 3.0 (Novo Nordisk), and Humalog and Humulin pens (Lilly).

Device preparation

Regardless of whether a patient chooses the prefilled or the reusable pen design, the techniques for dose preparation and insulin delivery are generally similar. Once a disposable needle is screwed on to the pen and the pen is primed, the patient simply dials to the appropriate dose, which can be seen in the device's display window and can be heard as audible clicks in many pen devices. The needle is inserted subcutaneously, and the plunger injection button is depressed to deliver the dose. One disadvantage of pen devices is that the injection itself takes slightly longer than does the traditional syringe injection. The pen needle should remain in the subcutaneous tissue for 5 seconds after complete depression of the plunger.

Insulin cartridges are available in either a 1.5-mL or 3.0-mL volume (150 U or 300 U, respectively) and are specific for the pen size (ie, a 150-U cartridge will not fit in a 300-U pen, and vice versa).

The following insulins are currently available in 1.5 mL cartridges: regular human insulin (Humulin R, Novolin R), human isophane insulin suspension (Humulin N, Novolin N), 70% human isophane insulin suspension with 30% regular human insulin (Humulin 70/30, Novolin 70/30), and insulin lispro (Humalog).

The cartridges should be stored in the refrigerator before use. However, once a cartridge is placed in a reusable pen, the pen can be kept at room temperature (<86°F) for a month, as long as it is away from direct heat and light.

The pen and cartridge configurations vary, so that only Lilly 3.0-mL cartridges fit Lilly, Becton Dickinson, and Owen Mumford 3.0-mL pens. Novo Nordisk 3.0-mL cartridges fit only 3.0-mL NovoPens. The Disetronic pens accept any insulin but require use of Disetronic cartridges.

The disposable needles that are attached to insulin pens have some advantages over standard syringe needles. Manufacturers offer pen needles that are one third shorter (12.7 mm) than standard-length needles and are a larger gauge (thus a smaller bore diameter) for greater patient comfort. Because the pen needle does not puncture the stopper of an insulin vial before injection, the needle maintains its sharpness and beveled angle, thereby potentially reducing the pain of injection, compared with the traditional vial-and-syringe technique.

Clinical studies

Although insulin pens have been available for more than a decade, few clinical studies in the United States have evaluated their use. After the pen's introduction in 1985, Jefferson and associates (6) evaluated patient preferences and blood-glucose control indexes in 10 adolescents with diabetes, aged 12 to 17 years. Over a 3-month period, mean glycosylated hemoglobin (HbA1c) levels decreased from $13.7 \pm 2.7\%$ to $11.7 \pm 3.4\%$. Most patients, including those who had increased their injections from once daily to four times a day, reported the pen's advantages outweighed the inconvenience of multiple injections. One of the first pen devices on the market was used in this study. Since that time, pens have undergone many significant improvements.

In 1993, Plevin and Sadur (7) assessed the acceptance of pen injections among 64 adult patients--19 with type 1 and 45 with type 2 diabetes. Most of the patients had been treated with insulin for 6 months to 43 years before the study; 22 of the 64 patients were new insulin users.

During the 4-week study, mean fasting blood glucose concentration decreased from 197 mg/dL to 171 mg/dL ($P<.05$), and none of the patients reported an episode of moderate or severe hypoglycemia. Patient comments regarding the pen were extremely positive: 98% reported the pen was convenient and easy to use, and 91% wanted to continue its use.

In an Italian study (1), the safety, efficacy, and acceptability of a prefilled insulin injection pen device was assessed in 60 patients with diabetes who were over 50 years of age and were using conventional insulin syringes. Hypoglycemic episodes did not differ significantly among patients using syringes compared with those using pens, and no marked hypoglycemia was noted. Blood glucose profiles were similar for both types of insulin administration, except for pre-lunch blood glucose values, which were lower with pen use (157 ± 52 mg/dL versus 166 ± 49 mg/dL [$P<.01$]). About 90% of patients administered insulin more quickly and easily with the pen than with the conventional syringe.

The investigators concluded that the prefilled insulin pen was safe, efficacious, and highly accepted in patients with diabetes over age 50 (1). Ease of accurate dosing is particularly important for older patients, who may have impaired vision, arthritis, or reduced motor coordination.

Two multicenter surveys (8) of 1,310 adult insulin users were conducted to assess the effect of prefilled and reusable pens on compliance with insulin, diet, and exercise regimens and on perceived well-being. Attitudes toward use of the pen and toward traditional syringe injections were also reviewed. Most patients found the pen easy to use (92% when using prefilled pens and 98% when using reusable pens). The survey showed that patients were very positive about the pen devices: 77% of pen users found it easier to comply with the insulin regimen using the pen than with conventional syringes, and 73% of pen users achieved more accurate insulin dosing than when syringes were used. More important, 85% of pen users never missed a scheduled injection, compared with 72% of patients using the vial-and-syringe method. In general, the fewer missed injections, the greater the likelihood of improved glycemic control and better therapeutic outcome. The investigators reported that patients' attitudes improved regarding insulin therapy; they had greater confidence in managing their disease (8).

Who benefits?

All patients with diabetes should be considered candidates for insulin pen devices. Diabetic patients with erratic eating habits may especially benefit. However, people who take regular or lispro insulin before meals or snacks and NPH insulin at bedtime usually need two pens, one for each type of insulin. Also, patients who take mixtures of two kinds of insulin in one syringe (eg, regular or lispro and NPH or lente other than the 70/30 premixed insulin) would need to use two pens and two injections for each dose. This often is less desirable than the single-syringe injection of mixed insulin.

Children, adolescents, and young adults

Children, whose perceptions of syringe injections include pain and rejection by peers, often have more positive feelings about the pens. The pens are particularly convenient for administering an accurate dose of insulin in a timely fashion for children with busy sports or activities schedules. In addition, the lower insulin doses typically used in children are easier to measure with the pen device. For young children, pediatric "POP" pens are available in various bright colors or patterns that easily differentiate rapid-acting insulin devices from those containing intermediate-acting insulin.

Because of the stereotypical association of syringes with illicit drug use, insulin administration is a special concern for young people with diabetes. In many elementary schools, the vial-and-syringe method of injecting insulin often is

relegated to the principal's office, which carries negative connotations. By comparison, the pen device generally can be used right in the classroom.

In one study (6), children reported that they could inject their prelunch insulin dose directly into their thigh or abdomen without leaving their desk or disrupting the classroom. The current pen devices do not require refrigeration, so they can be conveniently carried in a pocket, purse, or backpack for flexibility and proper timing of insulin dose. It appears logical to conclude that the use of pen devices by children and adolescents may decrease the social impact of diabetes in this age-group.

College students often have schedules that vary from day to day, with irregular hours of eating and activity (which may also include days with vigorous exercise or periods of carbohydrate loading). The ease of use of insulin pens and the flexibility of fitting insulin injections into a busy lifestyle may improve diabetes control with much less effort and disruption of normal college life.

Women with gestational diabetes

Treatment of women with gestational diabetes requiring pharmacologic therapy is limited to insulin. This is because oral agents may cause hypoglycemia or teratogenic effects in the fetus. Davidson and Roberts (9) reported, "the risk of complications in newborns of mothers with gestational diabetes is thought to be secondary to hyperglycemia during pregnancy and is markedly reduced when optimal control of glucose levels is established and maintained."

The convenience, flexibility, and ease of use of insulin pen devices can simplify treatment and reduce therapy-related stress for pregnant women during an already stressful time.

Older patients

The number of patients with diabetes over the age of 60 who are being treated with insulin is steadily growing. The majority of these patients are taking numerous medications, and many have some type of physical disability. As previously mentioned, insulin injections using a vial and syringe are associated with a high risk of error in this age-group (1).

In patients with vision problems, air bubbles that are drawn into the syringe may go unnoticed, leading to potentially tremendous variations in insulin delivery from day to day. Not only do insulin pens improve dosing accuracy and compliance, they also may be easier for patients with compromised fine-motor coordination to use. Therefore, the older person who has special challenges (eg, visual problems, tremor, poor injection technique) may particularly appreciate the pen (10).

Summary

Results of landmark studies such as the Diabetes Control and Complications Trial (11) and the United Kingdom Prospective Diabetes Study (12) are encouraging patients with diabetes and health professionals alike to strive to achieve and maintain the best possible glucose control. Insulin pens have the potential to become a major asset for improving compliance among diabetic patients. These devices offer substantial improvements in convenience, freedom, and flexibility for all insulin-using patients. Furthermore, more accurate dosing associated with use of the pen may hold the key to better long-term outcomes.

References

1. **Coscelli C, Lostia S, Lunetta M, et al.** Safety, efficacy, acceptability of a pre-filled insulin pen in diabetic patients over 60 years old. *Diabetes Res Clin Pract* 1995;28(3):173-7

2. **Smits JPhH, Schop C, Blok G.** A comparative study between two insulin pen injection devices. *Acta Therapeutica* 1993;19:15-22
3. **Bohannon NJV, Jack DB.** Type II diabetes: tips for managing your older patients. *Geriatrics* 1996;51(3):28-35
4. **Mey A, Gille Y, Thivolet CH.** Carriage of staphylococcus aureus and local infections in diabetic outpatients treated with insulin pen. (Letter) *Diabetes Care* 1990;13(4):451-2
5. **Le Floch JP, Herbreteau C, Lange F, et al.** Biologic material in needles and cartridges after insulin injection with a pen in diabetic patients. *Diabetes Care* 1998;21(9):1502-4
6. **Jefferson IG, Marteau TM, Smith MA, et al.** A multiple injection regimen using an insulin injection pen and pre-filled cartridged soluble human insulin in adolescents with diabetes. *Diabet Med* 1985;2(2):493-7
7. **Plevin S, Sadur C.** Use of a prefilled insulin syringe (Novolin Prefilled) by patients with diabetes. *Clin Ther* 1993;15(2):423-31
8. **Graff MR, McClanahan MA.** Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe. *Clin Ther* 1998;20(3):486-96
9. **Davidson JA, Roberts VL.** Gestational diabetes: ensuring a successful outcome. *Postgrad Med* 1996;99(3):165-72
10. **American Diabetes Association: Position statement.** Insulin administration. *Diabetes Care* 1997;20(Suppl 1):S46-9
11. **The Diabetes Control and Complications Trial Research Group.** The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 1993;329(14):977-86
12. **UK Prospective Diabetes Study (UKPDS) Group.** Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 1998;352(9131):837-53